// App-Quantinova.ai

60 : Upadacitinib as monotherapy: a phase 3 randomised controlled double-blind study in patients with active rheumatoid arthritis and inadequate response to methotrexate

Researchers

Presenter

  • J S Smolen

Principal Investigators

  • S Cohen

  • P Emery

  • W Rigby

  • Y Tanaka

  • Y Zhang

  • A Friedman

  • A A Othman

  • H S Camp

  • A L Pangan

Medical Centers

  • Rheumatology, Medical University Vienna, Vienna, -

  • Rheumatology, Metroplex Clinical Research Center, Dallas, TX

  • Leeds Inst of Rheumatic & Musculoskeletal Medicine, Leeds NIHR BRC, Leeds, UNITED KINGDOM

  • Rhematology, Dartmouth College, Dartmouth, NH

  • Univ of Occupational and Environmental Health, Univ of Occupational and Environmental Health, Japan, JAPAN

  • Rhematology, AbbVie, N Chicago, United States, Chicago, IL

Locations

  • Austria

  • United States

  • United Kingdom

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Peripheral Nervous System

Disease

  • Rheumatoid arthritis

  • Charcot-Marie-Tooth disease, X-linked dominant, 1

Biomarkers

  • Plasminogen Activator, Urokinase

  • High sensitivity C-reactive protein

Drug/Treatment

  • Methotrexate

  • ABT-494

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved